“China is the second largest pharmaceutical market in the world, and the country has plans to significantly grow its pharmaceutical industry over the next five years,” said Dominic Hyde, vice president for Global Services at Peli BioThermal. “Our new network station will make temperature controlled shipping logistics more convenient for customers doing work in the broader Asia-Pacific region.”
China is a growing component in the global market for manufacturing and distribution of pharmaceuticals, including as the leading producer of active pharmaceutical ingredients and a top producer of generic drugs. Through the “Made in China 2025” plan, China aims to further grow its pharmaceutical industry, focusing on drug innovation through research and development. China’s pharmaceutical market continues to be an area of significant growth. According to the International Trade Administration, China’s pharmaceutical market value reached almost US$134 billion in 2018 and is expected to grow to US$161.8 billion by 2023.
The Shanghai market is home to several of China’s top 10 pharmaceutical manufacturers including Shanghai Pharmaceuticals and Shanghai Fosun Pharmaceutical, and is a base for world-leading pharma companies including Johnson & Johnson, Roche, Novartis, Pfizer, Bayer, AstraZeneca and GlaxoSmithKline. Shanghai joins Peli BioThermal’s network of more than 100 network stations and drop points around the world and is the fourth network station in the Asia-Pacific region.